6533b853fe1ef96bd12acceb

RESEARCH PRODUCT

Vinblastine and interferon-alpha-2a regimen in the treatment of metastatic renal cell carcinoma.

Luciano RausaSergio PalmeriNicola GebbiaVittorio GebbiaAnna Russo

subject

OncologyAdultMaleCancer Researchmedicine.medical_specialtyInterferon alpha-2VinblastineGastroenterology03 medical and health sciences0302 clinical medicineStable DiseaseRenal cell carcinomaPartial responseInternal medicinemedicineHumans030212 general & internal medicineInterferon Alpha 2aCarcinoma Renal CellAgedbusiness.industryInterferon-alphaGeneral MedicineMiddle Agedmedicine.diseaseKidney NeoplasmsRecombinant ProteinsVinblastineRegimenOncology030220 oncology & carcinogenesisToxicityInterferon Type IDrug Therapy CombinationFemalebusinessProgressive diseasemedicine.drug

description

Thirteen patients with histologically proven advanced and/or metastatic renal cell carcinoma (RCC) were treated with vinblastine (Velbe, Eli Lilly, Sesto Fiorentino, Italy) and interferon-alpha-2a (Roferon-A, Roche, Milan). Eleven out of 13 patients were evaluable. Eighteen percent of patients had partial response, 46 % stable disease (SD), and 36 % progressive disease (PD). The mean survival of responders was 228+ days, whereas the patients showing SD and PD had a mean survival of 154+ and 107+ days respectively. Toxicity, including influenza-like syndrome, fever, neurological and gastrointestinal side effects, was generally mild. However, medication with paracetamol was required in 82 % of cases. Our small study confirms that VBL and IFN-2a regimen is moderately active in RCC.

yearjournalcountryeditionlanguage
1990-02-01Tumori
10.1177/030089169007600117https://pubmed.ncbi.nlm.nih.gov/2321276